Trastuzumab Deruxtecan Improves First-Line Treatment for HER2-Mutated Lung Cancer

The Phase III DESTINY-Lung04 study indicates that trastuzumab deruxtecan significantly improved progression-free survival compared to standard chemotherapy in patients with HER2-mutated non-small cell lung cancer. This finding, reported by PHARMASTAR, marks a potential advancement in the first-line treatment for this specific type of lung cancer, offering a new, more effective option for patients.